Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma
NCT04835129
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This study is for people who have a type of cancer called multiple myeloma that has come back or isn't responding to treatments. The study has three parts: one where doctors check if you qualify, one where you get treatment for several months, and one where doctors follow up with you afterwards. The treatment part includes taking a few different medicines.
This study is for people who have a type of cancer called multiple myeloma that has come back or isn't responding to treatments. The study has three parts: one where doctors check if you qualify, one where you get treatment for several months, and one where doctors follow up with you afterwards. The treatment part includes taking a few different medicines.
Third Opinion AI Generated Synopsis
Trial Summary
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.
This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab with elotuzumab, pomalidomide, and dexamethasone and a follow-up phase.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
